Samsung Biologics secures over $3.6 bil. in orders so far this year
Samsung Biologics has hit the 5 trillion won ($3.67 billion) mark in its cumulative orders so far this year after adding 440.5 billion won of new contracts to its contract manufacturing backlog, the biotech firm said Monday. In its regulatory filing, Samsung Biologics said it signed two contracts with drugmakers in Europe and Asia, worth 242 billion won and 198.5 billion won, respectively. The contract manufacturing deals will last until the end of 2030 and 2033, respectively, and Samsung Biologics did not reveal further details, citing confidentiality agreements. With the latest contracts, the company has secured four new contracts worth 3.25 trillion won across the United States, Asia and Europe so far this year, which account for approximately 60 percent of its total orders of 5.4 trillion won that it secured in 2024. Samsung Biologics said the 5 trillion won mark reflects its solid growth and expansion in the global biopharmaceutical industry. Currently, Samsung Biologics' clients include 17 out of the world's top 20 drugmakers, securing orders worth $18.2 billion since its foundation
May 26, 2025By Nam Hyun-woo